These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 27742776

  • 21. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
    Jdey W, Thierry S, Russo C, Devun F, Al Abo M, Noguiez-Hellin P, Sun JS, Barillot E, Zinovyev A, Kuperstein I, Pommier Y, Dutreix M.
    Clin Cancer Res; 2017 Feb 15; 23(4):1001-1011. PubMed ID: 27559053
    [Abstract] [Full Text] [Related]

  • 22. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.
    Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, Kaye S, Molife LR, Gelmon KA, Robertson JD, Mann H, Ho TW, Coleman RL.
    Ann Oncol; 2016 Jun 15; 27(6):1013-1019. PubMed ID: 26961146
    [Abstract] [Full Text] [Related]

  • 23. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
    Shah PD, Wethington SL, Pagan C, Latif N, Tanyi J, Martin LP, Morgan M, Burger RA, Haggerty A, Zarrin H, Rodriguez D, Domchek S, Drapkin R, Shih IM, Smith SA, Dean E, Gaillard S, Armstrong D, Torigian DA, Hwang WT, Giuntoli R, Simpkins F.
    Gynecol Oncol; 2021 Nov 15; 163(2):246-253. PubMed ID: 34620496
    [Abstract] [Full Text] [Related]

  • 24. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE, Kennedy RD.
    Oncologist; 2016 May 15; 21(5):586-93. PubMed ID: 27022037
    [Abstract] [Full Text] [Related]

  • 25. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
    Liu JF, Matulonis UA.
    Curr Oncol Rep; 2016 May 15; 18(5):29. PubMed ID: 26984416
    [Abstract] [Full Text] [Related]

  • 26. Dissecting PARP inhibitor resistance with functional genomics.
    Pettitt SJ, Lord CJ.
    Curr Opin Genet Dev; 2019 Feb 15; 54():55-63. PubMed ID: 30954761
    [Abstract] [Full Text] [Related]

  • 27. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A, Leary A.
    Bull Cancer; 2017 Nov 15; 104(11):971-980. PubMed ID: 29054544
    [Abstract] [Full Text] [Related]

  • 28. BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.
    Faraoni I, Compagnone M, Lavorgna S, Angelini DF, Cencioni MT, Piras E, Panetta P, Ottone T, Dolci S, Venditti A, Graziani G, Lo-Coco F.
    Biochim Biophys Acta; 2015 Mar 15; 1852(3):462-72. PubMed ID: 25483710
    [Abstract] [Full Text] [Related]

  • 29. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    Hijaz M, Chhina J, Mert I, Taylor M, Dar S, Al-Wahab Z, Ali-Fehmi R, Buekers T, Munkarah AR, Rattan R.
    Gynecol Oncol; 2016 Aug 15; 142(2):323-31. PubMed ID: 27282964
    [Abstract] [Full Text] [Related]

  • 30. Experiencia con el uso de olaparib en pacientes con cáncer de ovario.
    Gallardo-Rincón D, Alamilla-García G, Montes-Servín E, Morales-Vázquez F, Cano-Blanco C, Coronel-Martínez J, Bahena-González A, Gerson-Cwilich R, Isla-Ortiz D, Toledo-Leyva A, Montes-Servín E, Michel-Tello D, Espinosa-Romero R.
    Gac Med Mex; 2019 Aug 15; 155(6):585-589. PubMed ID: 31787769
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer.
    Cheng LJ, Wong G, Chay WY, Ngeow J, Tan Y, Soon SS, Aziz MIA, Pearce F, Ng K.
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun 15; 21(3):441-448. PubMed ID: 33593205
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
    Chao OS, Goodman OB.
    Mol Cancer Res; 2014 Dec 15; 12(12):1755-66. PubMed ID: 25127709
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
    Lheureux S, Bruce JP, Burnier JV, Karakasis K, Shaw PA, Clarke BA, Yang SY, Quevedo R, Li T, Dowar M, Bowering V, Pugh TJ, Oza AM.
    J Clin Oncol; 2017 Apr 10; 35(11):1240-1249. PubMed ID: 28221868
    [Abstract] [Full Text] [Related]

  • 38. A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair.
    Parrotta R, Okonska A, Ronner M, Weder W, Stahel R, Penengo L, Felley-Bosco E.
    J Thorac Oncol; 2017 Aug 10; 12(8):1309-1319. PubMed ID: 28389374
    [Abstract] [Full Text] [Related]

  • 39. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Wang D, Li C, Zhang Y, Wang M, Jiang N, Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H, Liu P.
    Gynecol Oncol; 2016 Sep 10; 142(3):548-56. PubMed ID: 27426307
    [Abstract] [Full Text] [Related]

  • 40. Resurrection of PARP Inhibitors in Breast Cancer.
    Lyons TG, Robson ME.
    J Natl Compr Canc Netw; 2018 Sep 10; 16(9):1150-1156. PubMed ID: 30181424
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.